Literature DB >> 23706983

NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.

Matthew Dyer, Joanna Richardson, Janet Robertson, Jane Adam.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23706983     DOI： 10.1016/S1470-2045(13)70248-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

Review 1.  Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy.

Authors:  Shigeo Fuji; Arnon Nagler; Mohamad Mohty; Bipin Savani; Roni Shouval
Journal:  Bone Marrow Transplant       Date:  2020-01-13       Impact factor: 5.483

2.  Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary.

Authors:  M B Hannouf; E Winquist; S M Mahmud; M Brackstone; S Sarma; G Rodrigues; P Rogan; J S Hoch; G S Zaric
Journal:  Pharmacogenomics J       Date:  2016-03-29       Impact factor: 3.550

3.  Molecular imaging-monitored radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus-thymidine kinase gene therapy for rat orthotopic ovarian cancer.

Authors:  Yaying Li; Shuhui Zhao; Feng Zhang; Guangxin Jin; Yiming Zhou; Peicheng Li; David Shin; Xiaoming Yang
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

4.  Timed, sequential administration of paclitaxel improves its cytotoxic effectiveness in a cell culture model.

Authors:  Viktória Fisi; Emese Kátai; Péter Bogner; Attila Miseta; Tamás Nagy
Journal:  Cell Cycle       Date:  2016-04-22       Impact factor: 4.534
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.